On November 19, 2024, UnicoCell’s (6794) patented manufacturing technology for exosome resource material, high-concentration stem cell conditioned media, has been awarded the Bronze Award in Manufacturing Technology Category of the 2024 National Pharmaceutical Technology & Research Development Award (NPRDA), which is the only award in Taiwan jointly organized by the Ministry of Health and Welfare and the Ministry of Economic Affairs. This Bronze award highly recognizes UnicoCell's patented manufacturing technology and the superior quality of exosome resource material, Stem Cell conditioned media.
The “National Pharmaceutical Science and Technology Research and Development Awards(NPRDA)” is the most prestigious government award in biotechnology field. Biotech companies show vigorously anticipation and fiercely contest for Gold, Silver, and Bronze Awards in 3 categories every year, including 'Pharmaceuticals,' 'Medical Devices,' and 'Manufacturing Technology.' In 2021, UnicoCell won the highly competitive Gold Award in the "Pharmaceuticals" category by its stem cell new drug, ELIXCYTE®. In 2023, UnicoCell earned an Honorable Mention in the "Medical Devices" category by its cryogenic vial, UnicoVial®, which is the only qualified cell drug container with medical device certificate in Taiwan. Furthermore, this year, UnicoCell was awarded the Bronze Medal in the "Manufacturing Technology" category by the patented manufacturing technology of exosome resource material, Stem Cell conditioned media. With all the honors, UnicoCell has scored a grand slam in this exclusive national award. This is also demonstrating that UnicoCell is widely recognized by its high quality and integrity in stem cell research and development.
The patented manufacturing technology of exosome resource material awarded to UnicoCell is characterized by the cell expansion technology using a three-dimensional culture and bioreactor system, along with a special preservation technique to maintain optimal activity of exosome resource material, stem cell conditioned media. This award-winning manufacturing technology significantly enhances the concentration, purity, and yield of exosome resource material compared to traditional methods, achieving simultaneous improvements in both quality and quantity. This is not only an excellent raw material for cosmetics, but also a promising starting material for medical applications, for completing preclinical animal safety studies of pharmaceutical products.
UnicoCell’s exosome resource material with this award-winning manufacturing technology has been acknowledged by US FDA as Master File (MF), registered with PCPC INCI name and registered as Japan's cosmetic ingredient. Moreover, UnicoCell’s animal resourced exosome products have been tested and shown significant efficacy. In addition to the expected growth revenue of the exosome products, UnicoCell is also undertaking clinical trials for knee osteoarthritis (Phase III recruiting) and chronic kidney disease (Phase II completed). Both clinical trials are the potential candidates for Regenerative Medicine Act Taiwan for conditioned approval and the great opportunities in licensing out.
Director-General Chuang Sheng-Hong of the Taiwan Food and Drug Administration (TFDA), Ministry of Health and Welfare, with the UnicoCell team.
Contact: Eileen Chen
Phone: 886-2-27922699
Mail: info@unicocell.com